Evidence map›Paper›PMID 31009702›Full record

ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2019

Cost-effective care in eosinophilic esophagitis.

Evan S Dellon

Open access · greenAbstract readReview
In one paragraph

Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Economic burden of eosinophilic esophagitis in the first year after diagnosis in Spain: A direct medical cost analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Observational
  3. A Qualitative Exploration of Australian Patients' and Parents' Perspectives in Optimising the Management of Eosinophilic Esophagitis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Prevalence and Costs of Eosinophilic Esophagitis in the United States.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Validation of the Short-Form Esophageal Hypervigilance and Anxiety Scale.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Distal esophagus is the most commonly involved site for strictures in patients with eosinophilic esophagitis.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Evan S DellonCenter for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC. Electronic address: edellon@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

The Impact of COVID-19 on People Living with Rare Diseases and Their FamiliesU2CTR002818 · NCATS · CINCINNATI CHILDRENS HOSP MED CTR · PI Maurizio Macaluso · 2019 to 2026
$51.2M
TRAINING (CAREER DEVELOPMENT) COMPONENTU54AI117804 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI GLENN T FURUTA · 2014 to 2026
$18.5M
Budesonide versus fluticasone for treatment of eosinophilic esophagitisR01DK101856 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DELLON, EVAN SAMUEL · 2014 to 2018
$1.7M
NCATS NIH HHS U2C TR002818NIAID NIH HHS U54 AI117804NIDDK NIH HHS R01 DK101856
6 · The paper itself

Abstract

objectiveTo examine costs related to eosinophilic esophagitis (EoE), understand the source of these costs, discuss a possible approach for cost-effective care in EoE, and identify areas for future research in this topic. DATA SOURCES/STUDY SELECTIONS: Narrative review of the literature from 1977 (first description of EoE) to March 2019, focusing on costs and cost-effectiveness analyses in EoE.

resultsHigh costs in EoE can be related to diagnostic delays, requirement for upper endoscopy with biopsy for diagnosis and monitoring of disease activity, expensive medications currently used off-label, increased food costs related to dietary elimination treatment, frequent doctor visits with subspecialists, and complications or disease exacerbations. Provision of cost-effective care in EoE is an understudied area, and a patient-centric approach is key. There are multiple areas in which future research can make an impact. These include determining predictors of treatment response, minimally or noninvasive methods to monitor disease activity, and validation of the use of multidisciplinary care.

conclusionEosinophilic esophagitis (EoE) is considered to be a rare disease, but the costs of care and burden of disease attributed to EoE are substantial. However, few studies examine either the costs related to EoE or the approach to cost-effective care for the EoE patient. To provide cost-effective care, a patient-centric approach and shared decision-making model are optimal. In addition, a rational strategy for EoE diagnosis and initial treatment, effective maintenance therapy for disease control and ideally to prevent complications, and appropriate long-term monitoring are all required.

Indexed as

Cost-Benefit AnalysisDecision Making, SharedEosinophilic EsophagitisHealth Care CostsHumansPatient-Centered CareRare Diseases

Identifiers

PMID31009702
PMCPMC6679981
OpenAlexW2938904193

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.